KERATOCONUS TESTING CONSENSUS STATEMENT: Understanding the Incidence and Impact of Keratoconus in Corneal Refractive Surgery & Reviewing New Standards to Preemptively Identify These Patients

KERATOCONUS TESTING CONSENSUS STATEMENT Understanding the Incidence and Impact of Keratoconus in Corneal Refractive Surgery
Details
Download PDF
  • Overview

    This continuing medical education (CME/CE) activity captures content from two roundtable discussions.

    ACTIVITY DESCRIPTION
    World class leaders assembled to discuss and vote on best practices and guidelines for understanding the incidence and impact of keratoconus in corneal refractive surgery and reviewing new standards to preemptively identify these patients. Topics of discussion included defining the fundamental etiology and progression of keratoconus, identifying the prevalence and demographics of keratoconus in various patient populations, diagnosing keratoconus and the importance of early detection using genetic testing, as well as the impact of keratoconus on patient and refractive surgery practices. The results of that discussion are summarized in this supplement.

    TARGET AUDIENCE
    This certified CE/CME activity is designed for ophthalmologists and optometrists.

    This activity is supported by an unrestricted educational grant from Avellino.

  • Learning Objectives

    Upon completion of this activity, the participant should be able to:

    • Define etiology and progression of keratoconus, understand how refractive surgery can exacerbate these conditions, and review the impact this has on visual outcomes and quality of life
    • Describe the prevalence of the refractive surgery patients developing keratoconus in various patient populations
    • Identify the accuracy of various conventional and new genetic testing metrics for identifying refractive surgery patients who may be at risk for developing keratoconus
    • Recommend diagnostic work-up protocols and pre-emptive testing indications for various groups of refractive surgery patients to maximize the diagnosis of keratoconus suspects
    • Review treatment options for refractive surgery candidates who have or are likely to develop keratoconus
    • Accreditation

      ACCREDITATION STATEMENT
      This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Evolve Medical Education LLC (Evolve) and The Fundingsland Group. Evolve is accredited by the ACCME to provide continuing medical education for physicians.

      DESIGNATION STATEMENT

      Evolve Medical Education designates this enduring material for a maximum of 1.5 AMA PRA Category 1 Credits™.
      Physicians should claim only the credit commensurate with the extent of their participation in the activity.
       

      Evolve Medical Education LLC (Evolve) is an approved COPE administrator.
      Sponsored by:
      This activity, COPE Activity Number , is accredited by COPE for continuing education for optometrists. 
      This course is approved for 1.5 hours CE. 
      Course Approval: 73479-AS
      Activity Approval: 122198

    • Participation Method

      In order to obtain credit, proceed through the program, complete the post-test, evaluation and submit for credit.

    • Faculty and Disclosures

      Eric D. Donnenfeld, MD

      Eric D. Donnenfeld, MD

      Ophthalmic Consultants of Long Island and Connecticut
      Trustee, Dartmouth Medical School
      Clinical Professor of Ophthalmology
      New York University
      New York, NY


      S. Barry Eiden, OD, FAAO

      S. Barry Eiden, OD, FAAO

      Program Director
      President and Medical Director
      North Suburban Vision Consultants
      Deerfield, Illinois
      Co-founder of the International
      Keratoconus Academy of
      Eye Care Professionals


      Melissa Barnett, OD, FAAO, FSLS, FBCLA

      Melissa Barnett, OD, FAAO, FSLS, FBCLA

      Principal Optometrist
      University of California, Davis, Eye Center
      Sacramento, CA


      Ashley Brissette, MD

      Ashley Brissette, MD

      Assistant Professor of Ophthalmology
      Cornea, Cataract, and
      Refractive Specialist
      Weill Cornell Medicine
      New York-Presbyterian Hospital
      New York, NY


      Mile Brujic, OD, FAAO

      Mile Brujic, OD, FAAO

      Partner
      Premier Vision Group
      Bowling Green, OH


      Gloria Chiu, OD, FAAO

      Gloria Chiu, OD, FAAO

      Associate Professor of Clinical
      Ophthalmology
      USC Roski Eye Institute
      University of Southern California
      Keck School of Medicine
      Los Angeles, CA


      John D. Gelles, OD

      John D. Gelles, OD

      Director
      Specialty Contact Lens Division
      Cornea and Laser Eye Institute (CLEI)
      and the CLEI Center for Keratoconus
      Teaneck, New Jersey
      Assistant Clinical Professor
      Rutgers New Jersey Medical School
      Newark, NJ


      Terry Kim, MD

      Terry Kim, MD

      Professor of Ophthalmology
      Duke University School of Medicine
      Chief, Cornea and External Disease Division
      Director, Refractive Surgery Service
      Duke University Eye Center
      Durham, NC


      Richard Lindstrom, MD

      Richard Lindstrom, MD

      Program Director
      Founder and Attending Surgeon
      Minnesota Eye Consultants
      Minneapolis, MN


      Andrew S. Morgenstern, OD, FAAO

      Andrew S. Morgenstern, OD, FAAO

      Vision Center of Excellence
      Walter Reed National Military
      Medical Center
      Bethesda, MD


      Neda Shamie, MD

      Neda Shamie, MD

      Partner
      Cornea, Cataract, and Refractive Surgeon
      Maloney-Shamie Vision Institute
      Los Angeles, California
      Clinical Associate Professor
      University of Southern California
      Keck School of Medicine
      Los Angeles, CA


      William B. Trattler, MD

      William B. Trattler, MD

      Cornea, Cataract, and
      Refractive Surgeon
      Center for Excellence in Eye Care
      Miami, Florida
      Clinical Associate Professor
      Herbert Wertheim College of
      Medicine at Florida
      International University
      Miami, FL


      Elizabeth Yeu, MD

      Elizabeth Yeu, MD

      Virginia Eye Consultants
      Medical Director, CVP Mid-Atlantic
      Cornea, Cataract, External Disease, and Refractive Surgery
      Assistant Professor, Department of Ophthalmology
      Eastern Virginia Medical School
      Norfolk, VA
       


      DISCLOSURE POLICY
      It is the policy of Evolve that faculty and other individuals who are in the position to control the content of this activity disclose any real or apparent conflicts of interest relating to the topics of this educational activity. Evolve has full policies in place that will identify and mitigate all conflicts of interest prior to this educational activity.

      The following faculty/staff members have the following financial relationships with commercial interests:

      Eric D. Donnenfeld, MD, has had a financial agreement or affiliation during the past year with the following commercial interests in the form of Consultant: Alcon Vision, Allegro, Allergan, Avellino, Bausch + Lomb, Carl Zeiss Meditec, CorneaGen, Covalent, BVI, Blephex, Dompé, ELT Sight, EyePoint Pharmaceuticals, Foresight, Glaukos, Ivantis, Johnson & Johnson Vision, Kala Pharmaceuticals, Katena, Lacripen, LensGen, Mati Therapeutics, MDBackline, Merck, Mimetogen, Nanowafer, Novabay, Novartis, Novaliq, Ocular Innovations, Oculis, Odyssey, Omega Ophthalmics, Oyster Point Pharma, Pfizer, Pogotec, Ocuhub, Omeros, PRN, RegenerEyes, ReTear, RPS, Shire, Strathspey Crown, Sun Pharmaceutical Industries, Surface, Tarsus, Tearlab, Tearscience, Thea, TLC Laser Centers, Veracity, Versant Ventures, Visionary Venture, and Visus. Stock/Shareholder: Avedro, CorneaGen, Covalent, ELT Sight, EyePoint Pharmaceuticals, Glaukos, Ivantis, Lacripen, LensGen, Mati Therapeutics, MDBackline, Mimetogen, Novabay, Ocuhub, Ocular Innovations, Oculis, Orasis Pharmaceutical, Pogotec, RegenerEyes, ReTear, RPS, Strathspey Crown, Surface, Tarsus, TearLab, Veracity, Versant Ventures, Visionary Ventures, and Visus.

      S. Barry Eiden, OD, FAAO, has had a financial agreement or affiliation during the past year with the following commercial interests in the form of Consultant/Speaker’s Bureau: Avellino, Glaukos, Oculus, and Oprovve. Grant/Research Support: Oculus.

      Melissa Barnett, OD, FAAO, FSLS, FBCLA, has had a financial agreement or affiliation during the past year with the following commercial interests in the form of Advisory Board: Azura, Bruder, Cooper Vision, Dompe, Everyday Contacts, EyeEco, Mojo Vision, Novartis, Ocusoft, Oyster Point,  Percept, and Raayonnova. Advisory Board/Consultant: Visus Therapeutics. Advisory Board/Speaker's Bureau: AAB, Acculens, Allergan, Bausch + Lomb, Contamac, Gas Permeable Lens Institute, JJVC Vistakon, RVL Pharmaceuticals, Scleral Lense Education Society, Synergeyes, Tangible Science, Tarsus. Speaker's Bureau: BCLA, Science Based Health, Sjogren's Syndrom Foundation, and STAPLE Program.

      Ashley Brissette, MD, has had a financial agreement or affiliation during the past year with the following commercial interests in the form of Consultant: Alcon Vision, Allergan, Bruder, Carl Zeiss Meditec, Eyevance, Kala Pharmaceuticals, and Ocular Therapeutix. Grant/Research Support: Alcon Vision.

      Mile Brujic, OD, FAAO, has had a financial agreement or affiliation during the past year with the following commercial interests in the form of Consultant: Akorn, Alcon Vision, Allergan, Bausch + Lomb Health, Blephex, Contamac, CSEye, Eyevance, Horizon Therapeutics, Kala Pharmaceuticals, Novartis, Sun Pharmaceutical Industries, VMax Vision, and Zea Vision. Speaker’s Bureau: Allergan, Bausch + Lomb Health, Kala Pharmaceuticals, Novartis, Optovue, Sun Pharmaceutical Industries, and Zea Vision. Grant/Research Support: Contamac.

      Gloria Chiu, OD, FAAO, has had a financial agreement or affiliation during the past year with the following commercial interests in the form of Consultant: Avedro/Glaukos and Visionary.

      John D. Gelles, OD, has had a financial agreement or affiliation during the past year with the following commercial interests in the form of Consultant and Speaker’s Bureau: Avedro, Avellino, Boston Sight, Blanchard Labs, Bausch + Lomb, Contamac, Glaukos, Oculus, Synergeyes, and Visionix. Devices: Boston Sight, Blanchard Labs, Oculus, and Ovitz. Grant/Research Support: Avedro, Avellino, Alcon Vision, CorneaGen, Glaukos, Oculus, and Ovitz. Speaker’s Bureau and Advisory Board: Gas Permeable Labs Institute and International Keratoconus Academy.

      Terry Kim, MD, has had a financial agreement or affiliation during the past year with the following commercial interests in the form of Consultant: Aerie Pharmaceuticals, Alcon Vision, Allergan, Avedro, Avellino Labs, Azura Ophthalmics, Bausch + Lomb, CorneaGen, Dompé, Eyenovia, Johnson & Johnson Vision, Kala Pharmaceuticals, Novartis, Ocular Therapeutix, Oculis, Omeros, Presbyopia Therapies, Sight Sciences, Simple Contacts, Surface, and Carl Zeiss Meditec. Stock/Shareholder: Avellino Labs, CorneaGen, Eyenovia, Kala Pharmaceuticals, Ocular Therapeutix, Omeros, Presbyopia Therapies, and Simple Contacts.

      Richard Lindstrom, MD, has had a financial agreement or affiliation during the past year with the following commercial interests in the form of Consultant: Acufocus, Aerie Pharmaceuticals, Alcon Vision, Allegro, Bausch Health, Johnson & Johnson Vision, Kala Pharmaceuticals, Imprimis, Surface Ophthamics, Novartis, and Ocular Therapeutix.

      Andrew S. Morgenstern, OD, FAAO, has had a financial agreement or affiliation during the past year with the following commercial interests in the form of Consultant: American Optometric Association. Grant/Research Support: International Keratoconus Academy. Speaker’s Bureau: Alcon Vision, Allergan, Glaukos, and Johnson & Johnson Vision.   

      All quotes from Dr. Morgenstern are his personal opinion only. It does not reflect the opinion of the US Department of Defense, Defense Health Agency, Department of Veterans Affairs or any other US governmental organization or agency.

      Neda Shamie, MD, has had a financial agreement or affiliation during the past year with the following commercial interests in the form of Consultant: Alcon, Allergan, Avellino, Glaukos, Staar Surgical, and Tarsus.

      William B. Trattler, MD, has had a financial agreement or affiliation during the past year with the following commercial interests in the form of Consultant: Alcon Vision, Bausch + Lomb, Carl Zeiss Meditec, CXLO, Johnson & Johnson Vision, and Oculus. Speaker’s Bureau: Alcon Vision, Carl Zeiss Meditec, Johnson & Johnson Vision, and Oculus. Stock/Shareholder: Avedro, CXLO, and Trefoil.

      Elizabeth Yeu, MD, has had a financial agreement or affiliation during the past year with the following commercial interests in the form of Consultant: Alcon Vision, Allergan, Avedro, Bausch + Lomb, BioTissue, Beaver Visitec, BlephEx, Bruder, CorneaGen, Dompé, Expert Opinion, EyePoint Pharmaceuticals, Guidepoint, Johnson & Johnson Vision, Kala Pharmaceuticals, LENSAE, Merck, Mynosys, Novartis, Ocular Science, Ocular Therapeutix, Ocusoft, Omeros, Oyster Point Pharma, Science Based Health, Shire, Sight Sciences, Sun Pharma, Surface, Thea, Tarsus, TopCon, TearLab, Visus Therapeutics, and Zeiss. Grant/Research Support: Alcon Vision, BioTissue, Ocular Science, TopCon, and TearLab. Stock/Shareholder: BlephEx, CorneaGen, Melt, Ocular Science, Oyster Point Pharma, and Tarsus.

      The Evolve staff and planners have no financial relationships with commercial interests. Diane Angelucci, writer, and Nisha Mukherjee, MD, peer reviewer, have no financial relationships with commercial interests.

    • Disclaimer

      OFF-LABEL STATEMENT
      This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The opinions expressed in the educational activity are those of the faculty. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

      DISCLAIMER
      The views and opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of Evolve, The Fundingsland Group, Cataract & Refractive Surgery Today, Modern Optometry, or Avellino.

    • System Requirements

      • Supported Browsers (2 most recent versions):
        • Google Chrome for Windows, Mac OS, iOS, and Android
        • Apple Safari for Mac OS and iOS
        • Mozilla Firefox for Windows, Mac OS, iOS, and Android
        • Microsoft Edge for Windows
      • Recommended Internet Speed: 5Mbps+

    • Publication Dates

      Expiration Date:

    1.50 credits
    Completing the pre-test is required to access this content.
    Completing the pre-survey is required to view this content.

    Ready to Claim Your Credits?

    You have attempts to pass this post-test. Take your time and review carefully before submitting.

    Good luck!

    Register

    We're glad to see you're enjoying Evolve Medical Education…
    but how about a more personalized experience?

    Register for free